New drug duo battles tough ovarian cancer

NCT ID NCT04729387

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether combining two targeted drugs, alpelisib and olaparib, works better than standard chemotherapy for women with a specific type of advanced ovarian cancer that has stopped responding to platinum-based treatments. The trial enrolled 358 women whose cancer had progressed despite prior therapies and who do not have a specific genetic mutation (BRCA). The goal was to see if the combination could better control the cancer's growth and improve survival.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arizona Oncology Associates

Phoenix, Arizona, 85016, United States
Avera Cancer Institute

Sioux Falls, South Dakota, 57106, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Florida Cancer Specialists

Fort Myers, Florida, 33901, United States
Florida Cancer Specialists

West Palm Beach, Florida, 33401, United States
HonorHealth

Phoenix, Arizona, 85016, United States
Maryland Oncology Hematology P A

Silver Spring, Maryland, 20904, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Ctr

New York, New York, 10065, United States
Novartis Investigative Site

CABA, Buenos Aires, C1125ABD, Argentina
Novartis Investigative Site

Buenos Aires, C1012AAR, Argentina
Novartis Investigative Site

Caba, C1015ABO, Argentina
Novartis Investigative Site

Bedford Park, South Australia, 5041, Australia
Novartis Investigative Site

Shepparton, Victoria, 3630, Australia
Novartis Investigative Site

Sydney, 2031, Australia
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Brussels, 1000, Belgium
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Namur, 5000, Belgium
Novartis Investigative Site

Belo Horizonte, Minas Gerais, 30130-100, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 04014-002, Brazil
Novartis Investigative Site

Calgary, Alberta, T2N 5G2, Canada
Novartis Investigative Site

Vancouver, British Columbia, V5Z 4E6, Canada
Novartis Investigative Site

London, Ontario, N6A 5W9, Canada
Novartis Investigative Site

Toronto, Ontario, M4N 3M5, Canada
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Jinan, 250012, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Tianjin, 300480, China
Novartis Investigative Site

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site

Nový Jičín, 741 01, Czechia
Novartis Investigative Site

Prague, 128 08, Czechia
Novartis Investigative Site

Herlev, DK-2730, Denmark
Novartis Investigative Site

Odense C, 5000, Denmark
Novartis Investigative Site

Kuopio, FIN-70211, Finland
Novartis Investigative Site

Tampere, FIN-33521, Finland
Novartis Investigative Site

Turku, FIN 20521, Finland
Novartis Investigative Site

Besançon, 25030, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Paris, 75012, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Villejuif, 94800, France
Novartis Investigative Site

Mannheim, Baden-Wurttemberg, 68305, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Essen, 45136, Germany
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Milan, MI, 20141, Italy
Novartis Investigative Site

Roma, RM, 00168, Italy
Novartis Investigative Site

Vicenza, VI, 36100, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, 50586, Malaysia
Novartis Investigative Site

Kota Kinabalu, Sabah, 88996, Malaysia
Novartis Investigative Site

Kuching, Sarawak, 93586, Malaysia
Novartis Investigative Site

Kuala Lumpur, 59100, Malaysia
Novartis Investigative Site

Monterrey, Nuevo León, 64460, Mexico
Novartis Investigative Site

Mexico City, 04700, Mexico
Novartis Investigative Site

Eindhoven, 5623 EJ, Netherlands
Novartis Investigative Site

Loures, 2674-514, Portugal
Novartis Investigative Site

Porto, 4200-072, Portugal
Novartis Investigative Site

Arkhangelsk, 163045, Russia
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Bratislava, 83310, Slovakia
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Taichung, 407219, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Izmir, Karsiyaka, 35575, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Adana, Yuregir, 01230, Turkey (Türkiye)
Novartis Investigative Site

Ankara, 06520, Turkey (Türkiye)
Novartis Investigative Site

Glasgow, G12 0YN, United Kingdom
Novartis Investigative Site

London, SE1 9RT, United Kingdom
Novartis Investigative Site

Manchester, M20 2BX, United Kingdom
Oncology Hematology Care Inc

Cincinnati, Ohio, 45242, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Texas Oncology

Dallas, Texas, 75246, United States
Texas Oncology Northeast Texas

Tyler, Texas, 75702, United States
Texas Oncology P A

Bedford, Texas, 76022, United States
Texas Oncology P A

San Antonio, Texas, 78217, United States
University Of Cincinnati

Cincinnati, Ohio, 45267, United States

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER